Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Ipsen S.A. ADR (IPSEY) Q4 2018 Results Earnings Conference Call February 14, 2019, 08:30 AM ET Company Participants David Meek - CEO Aymeric Chatelier - Executive VP & CFO Conference Call Participants Richard Vosser - JPMorgan Presentation Operator David Meek ...
The following slide deck was published by Ipsen S.A. ADR in conjunction with their 2018 Q4 earnings Read more ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its financial results for the full year 2018. Financial highlights Group sales growth of 16.6% as reported and 20.1% at constant exchange rates 1 , driven by...
International survey presented at TOXINS 2019 reveals hidden burden of spasticity 1 Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190117005697/en/ Carenity Infographic Ipsen (Euronext: IP...
Safety, tolerability and pharmacodynamics of BoNT-E demonstrated in Phase I study 1 Regulatory News: Results of the first in-human study of a recombinant neurotoxin are being presented at the TOXINS International Conference in Copenhagen. Ipsen’s recombinant BoNT serotype ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that abobotulinumtoxinA (Dysport ® ) and its recombinant botulinum toxins pipeline are the subject of 50 posters at the 2019 TOXINS International Conference. Results are presented from basic science ( in vivo , in v...
– Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting – Regulatory News: Exelixis, Inc. (Nasdaq: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced the initiation of COSMIC-312, a phase 3 pivotal trial...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177 Lu-IPN01087 (formerly known as 3BP-227). IPN01087 is a compound that targets cancer cells in patients with advan...
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation PARIS , Nov. 19, 2018 /PRNewswire/ -- Ipsen (Euronext: IPN; OTC Pink: IPSEY) based in Paris , and focused on Specialty Care biopharmaceuticals...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx ® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval al...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...